A comprehensive approach to dermatocosmetological care of patients with body weight reduction during incretins therapy: From age-related characteristics of the structure of the subtlets to annual correction protocol
https://doi.org/10.21518/ms2026-091
Abstract
Introduction. In Russia, the proportion of the population with excessive weight reaches 60–62%, with class 1–3 obesity diagnosed in 20–22%.
Aim. To develop and substantiate a comprehensive protocol of dermatological support for obese patients on the background of incretin therapy, aimed at preventing and correcting undesirable skin and soft tissue changes associated with rapid weight loss.
Materials and methods. The analysis of modern literature data on the pathophysiological mechanisms of the effect of obesity on skin, muscle and bone tissue, as well as on the systemic effects of incretin drugs (GLP-1 receptor agonists and the double agonist GIP/GLP-1 tirzepatide) is carried out. Morphofunctional features of the skin and subcutaneous fat in various age and gender groups, changes in obesity and in the process of rapid weight loss, regardless of the method of body weight reduction, are considered. Based on the analysis of the evidence base and clinical experience, a step-by-step algorithm for patient management has been developed.
Results. It has been established that obesity has a multifactorial negative effect on the skin: adipokine imbalance, chronic systemic inflammation (increased TNF-α, IL-6), suppression of type I collagen synthesis, impaired microcirculation, vitamin D deficiency. Rapid weight loss exacerbates these changes, leading to gravitational ptosis, facial lipoatrophy, deepening of nasolabial and mental folds, reduction of turgor, sagging skin (the phenomenon of “Ozempic face”). An annual protocol of dermatological support is proposed.
Conclusion. The proposed protocol, based on the principles of phasing, proactivity, and an integrated and personalized approach, minimizes the undesirable aesthetic effects of rapid weight loss. Effective patient management requires interdisciplinary collaboration between an endocrinologist, a nutritionist, and a cosmetologist.
About the Authors
E. V. Svechnikova
Russian Biotechnological University;
Polyclinic No. 1 of the Administrative Department of the Russian Federation
Russian Federation
Russian Federation
Elena V. Svechnikova, Dr. Sci. (Med.), Professor, Professor of the Department of Skin and Venereal Diseases; Head of the Department of Dermatovenereology and Cosmetology
11, Volokolamskoe Shosse, Moscow, 125080;
26/28, Sivtsev Vrazhek Lane, Moscow, 119002
S. E. Zhufina
Flow Center MSK-Leninsky (Fomin Clinic)
Russian Federation
Russian Federation
Svetlana E. Zhufina, Dermatovenereologist
107, Bldg. 1, Leninsky Ave., Moscow, 119421
M. A. Morzhanaeva
BTL Russia
Russian Federation
Russian Federation
Maria A. Morzhanaeva, Cand. Sci. (Med.), Cosmetologist, Expert in the Development of the Aesthetic Field
35, Bldg. 2, Leningradsky Ave., Moscow, 125284
References
1. Demidova TY, Kislyak OA, Starodubova AV, Nikitin IG, Ushanova FO. Beyond BMI: We are discussing a new concept for the definition and diagnosis of clinical obesity. Meditsinskiy Sovet. 2025;19(6):86–98. (In Russ.) https://doi.org/10.21518/ms2025-183
2. Fighting obesity as a direction of national health care development. Obesity and Metabolism. 2022;19(1):4–6. (In Russ.) https://doi.org/10.14341/omet12865.
3. Mustafina SV, Vinter DA, Alferova VI. Influence of obesity on the formation and development of cancer. Obesity and Metabolism. 2024;21(2):205–214. (In Russ.) https://doi.org/10.14341/omet13025.
4. Mohajer N, Du CY, Checkcinco C, Blumberg B. Obesogens: How They Are Identified and Molecular Mechanisms Underlying Their Action. Front Endocrinol. 2021;12:780888. https://doi.org/10.3389/fendo.2021.780888.
5. Roshandel D, Lu T, Paterson AD, Dash S. Beyond apples and pears: sexspecific genetics of body fat percentage. Front Endocrinol. 2023;14:1274791. https://doi.org/10.3389/fendo.2023.1274791.
6. Lobstein T, Jackson-Leach R, Powis J, Brinsden H, Gray M. World Obesity Atlas 2023. World Obesity Federation; 2023. Available at: https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023.
7. Gómez-García I, Trepiana J, Fernández-Quintela A, Giralt M, Portillo MP. Sexual Dimorphism in Brown Adipose Tissue Activation and White Adipose Tissue Browning. Int J Mol Sci. 2022;23(15):8250. https://doi.org/10.3390/ijms23158250.
8. Witkam R, Gwinnutt JM, Humphreys J, Gandrup J, Cooper R, Verstappen SMM. Do associations between education and obesity vary depending on the measure of obesity used? A systematic literature review and meta-analysis. SSM Popul Health. 2021;15:100884. https://doi.org/10.1016/j.ssmph.2021.100884.
9. Kim H, Kim SE, Sung MK. Sex and Gender Differences in Obesity: Biological, Sociocultural, and Clinical Perspectives. World J Mens Health. 2025;43(4):758–772. https://doi.org/10.5534/wjmh.250126.
10. Bardhi O, Palmer BF, Clegg DJ. The evolutionary impact and influence of oestrogens on adipose tissue structure and function. Philos Trans R Soc Lond B Biol Sci. 2023;378(1885):20220207. https://doi.org/10.1098/rstb.2022.0207.
11. Ng M, Gakidou E, Lo J, Abate YH, Abbafati C, Abbas N et al. Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405(10481):813–838. https://doi.org/10.1016/S0140-6736(25)00355-1.
12. Lumish HS, O’Reilly M, Reilly MP. Sex Differences in Genomic Drivers of Adipose Distribution and Related Cardiometabolic Disorders: Opportunities for Precision Medicine. Arterioscler Thromb Vasc Biol. 2020;40(1):45–60. https://doi.org/10.1161/ATVBAHA.119.313154.
13. Vilaca T, Evans A, Gossiel F, Paggiosi M, Eastell R, Walsh JS. Fat, adipokines, bone structure and bone regulatory factors associations in obesity. Eur J Endocrinol. 2022;187(6):743–750. https://doi.org/10.1530/EJE-22-0530.
14. Bagherifard A, Hemmatyar A, Khosravi K, Rouzbahani A, Mokhtari K, Yahyazedeh H, Tanzadehpanah H. The impact of obesity on bone health: molecular pathways, metabolic interactions, and associated pathologies. Int J Obes. 2026;50(1):87–115. https://doi.org/10.1038/s41366-025-01907-1.
15. Santamaría-Ulloa C, Lehning AJ, Cortés-Ortiz MV, Méndez-Chacón E. Frailty as a predictor of mortality: a comparative cohort study of older adults in Costa Rica and the United States. BMC Public Health. 2023;23(1):1960. https://doi.org/10.1186/s12889-023-16900-4.
16. Salukhov VV, Shustov SB, Petrankov KV. The impact of semaglutide and tirzepatide on skeletal muscle: Significant benefit or substantial risk? Meditsinskiy Sovet. 2025;19(16):195–206. (In Russ.) https://doi.org/10.21518/ms2025-467.
17. Yamane T, Tsukahara A, Oishi Y. Obesty-induced leptin resistance is directly involved in skin fragility by decreasing type I collagen synthesis. Biosci Biotechnol Biochem. 2026;90(2):234–242. https://doi.org/10.1093/bbb/zbaf171.
18. Shperling NV, Chaplygin AV, Chaplygina NV. Hyperglycemia in the focus of prevention of age-related skin changes. Meditsinskiy Sovet. 2025;19(14):184–192. (In Russ.) https://doi.org/10.21518/ms2025-360.
19. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, Stucky NL. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056–1064. https://doi.org/10.1001/jamainternmed.2024.2525.
20. Ding Y, Shi Y, Guan R, Yan S, Liu H, Wang Z et al. Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis. Pharmacol Res. 2024;199:107031. https://doi.org/10.1016/j.phrs.2023.107031.
21. Zaazouee MS, Hamdallah A, Helmy SK, Hasabo EA, Sayed AK, Gbreel MI et al. Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes. Diabetes Metab Syndr. 2022;16(6):102511. https://doi.org/10.1016/j.dsx.2022.102511.
22. Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol. 2021;12:645563. https://doi.org/10.3389/fendo.2021.645563.
23. Syed YY. Tirzepatide: First Approval. Drugs. 2022;82(11):1213–1220. https://doi.org/10.1007/s40265-022-01746-8.
24. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515. https://doi.org/10.1056/NEJMoa2107519.
25. Raičević BB, Belančić A, Mirković N, Janković SM. Analysis of Reporting Trends of Serious Adverse Events Associated with Anti-Obesity Drugs. Pharmacol Res Perspect. 2025;13(2):e70080. https://doi.org/10.1002/prp2.70080.
26. Lugovik IA, Babina AV, Arutyunyan SS, Ermolaeva DO, Saparova VB, Kobeleva TN et al. The first generic tirzepatide GP30931: physicochemical and biological similarity to the reference drug. Drug Development and Registration. 2025;14(2):54–74. (In Russ.) https://doi.org/10.33380/2305-2066-2025-14-2-2084.
27. Demidova TYu, Izmaylova MYa. New horizons in the management of metabolic diseases: Focus on the efficacy and safety of tirzepatide. FOCUS Endocrinology. 2025;6(3):12–23. (In Russ.) https://doi.org/10.62751/2713-0177-2025-6-3-03.
28. Ryan DH. Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice? J Obes Metab Syndr. 2021;30(3):196–208. https://doi.org/10.7570/jomes21033.
29. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315. https://doi.org/10.3390/molecules27134315.
30. Catalfamo L, De Ponte FS, De Rinaldis D. “Ozempic Face”: An Emerging Drug-Related Aesthetic Concern and Its Treatment with Endotissutal Bipolar Radiofrequency (RF)-Our Experience. J Clin Med. 2025;14(15):5269. https://doi.org/10.3390/jcm14155269.
31. Carboni A, Woessner S, Martini O, Marroquin NA, Waller J. Natural Weight Loss or “Ozempic Face”: Demystifying A Social Media Phenomenon. J Drugs Dermatol. 2024;23(1):1367–1368. https://doi.org/10.36849/JDD.7613.
32. Ridha Z, Fabi SG, Zubar R, Dayan SH. Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging. Aesthet Surg J. 2024;44(11):NP809–NP818. https://doi.org/10.1093/asj/sjae132.
33. Kim Chung le T, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T, Nakaya Y. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun. 2009;390(3):613–618. https://doi.org/10.1016/j.bbrc.2009.10.015.
34. Paschou IA, Sali E, Paschou SA, Tsamis KI, Peppa M, Psaltopoulou T et al. GLP-1RA and the possible skin aging. Endocrine. 2025;89(3):680–685. https://doi.org/10.1007/s12020-025-04293-w.
35. Burke OM, Sa B, Cespedes DA, Tosti A. Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications. Skin Appendage Disord. 2025;11(5):416–423. https://doi.org/10.1159/000544023.
Review
For citations:
Svechnikova EV, Zhufina SE, Morzhanaeva MA. A comprehensive approach to dermatocosmetological care of patients with body weight reduction during incretins therapy: From age-related characteristics of the structure of the subtlets to annual correction protocol. Meditsinskiy sovet = Medical Council. 2026;(2):160-168. (In Russ.) https://doi.org/10.21518/ms2026-091
Views:
52
JATS XML
Email this article 